Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Contraceptive

Therapeutic area intelligence for Contraceptive with 8 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 8
Catalysts: 0
Companies: 4

Companies

Annora Pharma →

Novast Labs →

Assets

Desogestrel →

Levonorgestrel →

Recent signals(8)

RegulatoryAugust 11, 2026

FDA accepts supplemental NDA for IMPLANON by ORGANON

The FDA has accepted a supplemental NDA for IMPLANON (NDA021529) submitted by ORGANON, with a review priority of STANDARD.

RegulatoryAugust 3, 2026

Lupin's ANDA201446 for Levonorgestrel Receives FDA AP Status

Lupin's ANDA201446 for Levonorgestrel has been granted Abbreviated Approval (AP) status by the FDA.

RegulatoryJuly 16, 2026

FDA Grants AP Status for ELINEST ANDA091105 by Novast Labs

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for ELINEST submitted by Novast Labs.

RegulatoryJuly 12, 2026

Lupin's ANDA201446 for Levonorgestrel Receives Standard Review Status

Lupin's ANDA201446 for Levonorgestrel has been submitted and is currently under standard review by the FDA.

RegulatoryJuly 12, 2026

FDA Grants AP Status for Desogestrel and Ethinyl Estradiol ANDA219670

The FDA has granted Abbreviated Approval (AP) status for ANDA219670, a combination of Desogestrel and Ethinyl Estradiol.

RegulatoryJune 27, 2026

Teva's ANDA219324 for Junel FE Receives Approval Status from FDA

Teva Pharmaceuticals' ANDA219324 for Junel FE has received an Approval Pending (AP) status from the FDA.

RegulatoryJune 27, 2026

FDA Accepts Supplement Application for TWIRLA by AGILE

The FDA has accepted a supplemental application for TWIRLA, a contraceptive patch containing ethynyl estradiol and levonorgestrel.

RegulatoryJune 25, 2026

FDA Accepts Supplemental Application for TWIRLA

The FDA has accepted a supplemental application for TWIRLA, a contraceptive patch containing ethynyl estradiol and levonorgestrel.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.